Navigation Links
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/19/2007

on day 42.

Study Results

RAV12 was moderately well-tolerated with fractionated dosing that allowed delivery of an "effective dose" (i.e. 1.5 mg/kg total dose over one week time) as 0.75 mg/kg twice weekly. The two primary side effects observed were Infusion-associated abdominal discomfort and diarrhea, and elevated liver function tests. Both side effects appear related to CMax as they tended to appear early on after dosing and tended to resolve rapidly after dosing, and were ameliorated by fractionated dosing.

Treatment with RAV12 demonstrated preliminary evidence of anti-tumor activity. One patient with refractory colorectal cancer experienced a partial remission with time to progression exceeding 8 months and one patient with advanced pancreatic cancer had a > 50% reduction in the relevant tumor marker, CA19-9 and experienced disease stability for more than five months.

As a result of these findings, future development of RAV12 both as single agent and in combination with chemotherapy is planned for 2008. The recommended dose and schedule for Phase 2 clinical study of RAV12 is 0.75 mg/kg twice weekly.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody which is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacio
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Transportation ... provider, announces winning the SDCE100 Award for ... & Demand Chain Executive magazine. Transportation ... consumer goods distributor quantify and control supply ... their highly competitive market. Deploying Transportation Insight,s ...
(Date:5/28/2015)... 28, 2015   Eli Lilly and Company (NYSE: ... host a webcast on June 11 to discuss data from ... rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will ... the EULAR Congress 2015 in Rome, Italy ... to11:00 a.m. Eastern Daylight Time. The live audio webcast can ...
(Date:5/28/2015)... , May 28, 2015 ... "Global mHealth Market (Device, Service, Application, Stakeholders and Geography) - ... 2014-2020", stated that the global mHealth market was ... expected to grow at a CAGR of 33.5% ... share in the global mHealth device market followed ...
Breaking Medicine Technology:Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 2Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 3Transportation Insight Wins SDCE100 Award for Delivering End-to-End Supply Chain Value 4Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 2mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 3mHealth Market to Grow at an Impressive CAGR of 33.5% During 2015 - 2020 - Allied Market Research 4
... Therapeutics Inc. today announced results from a Phase ... lesion growth and preserves visual acuity in patients with ... age-related macular degeneration ( AMD ). The data showed ... levels of 60 percent to 75 percent was predictive ...
... The New Hampshire Bio/Medical Council held its 2nd Annual Awards Dinner ... NH. During the evening, the Bio/Medical Council awarded Atrium Medical Corporation ... Business of the Year Award. In attendance ... Chief Operating Officer and Steve Vail, Group VP of Global Marketing. ...
Cached Medicine Technology:Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients 2Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients 3Atrium Recognized by New Hampshire Bio/Medical Council 2
(Date:5/28/2015)... (PRWEB) May 28, 2015 External Counterpulsation ... and all over the United States. There are a ... disease, who can experience symptoms of angina and these ... heart stents and/or bypass surgery. , “No option” patients ... to coronary artery disease that is considered unacceptable for ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 AMVETS National ... on the Commission on Care established by Congress to ... nation’s veterans. , Appointed to the commission by Mitch ... will be one of only 15 voting members on ... Choice and Accountability Act of 2014. The goal of ...
(Date:5/28/2015)... 28, 2015 Park Cities Pet Sitter is ... Training class starting Saturday, June 6th at 10:30am. ... 5831 McCommas Blvd in Dallas, with a maximum of six ... for five weeks, with no class being held over the ... $135. , In this Intermediate-to-Advanced level class, dogs will solidify ...
(Date:5/28/2015)... 2015 New Jersey Plastic Surgeon and ... world-class results. With over 30 years of experience ... in art, Dr. Rafizadeh knows what it takes to ... Plastic Surgery involves the principles of proportion, harmony and ... level of comfort and personalized care from the moment ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 As the summer ... to keep cool. It’s important to make safety a top ... sharing some swimming tips. , According to the Centers for ... the United States, not including boating incidents. Additionally, the National ... for children ages 1 to 4. , Amica is ...
Breaking Medicine News(10 mins):Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Splash! Amica Shares 6 Swimming Safety Tips 2
... , ... ... , ... ...
... ... and iPower™ - all together nowSM and available for download in the App ... ... Dynastream Innovations Inc. and iTMP Technology, a leader in digital, wireless health and ...
... ... ... ... ...
... that some states have cut breast cancer screening programs , ... to mammograms for women ages 40 to 49 has decreased ... by the U.S. Preventive Services Task Force, according to a ... average risk for breast cancer should start having mammograms every ...
... ST. LOUIS -- The extract from a vegetable that is ... chain of events that kills breast cancer cells and prevents ... Ratna Ray, Ph.D., professor in the department of pathology ... surprised that the extract from the bitter melon she cooks ...
... can help protect against symptoms of depression, but a study ... In patients diagnosed with clinical depression, belief in ... to a paper in the Journal of Clinical Psychology ... depression or bipolar depression at inpatient and outpatient psychiatric care ...
Cached Medicine News:Health News:State of Oregon Department of Human Services Selects Netsmart Technologies for Comprehensive Behavioral Healthcare Integration Project 2Health News:State of Oregon Department of Human Services Selects Netsmart Technologies for Comprehensive Behavioral Healthcare Integration Project 3Health News:State of Oregon Department of Human Services Selects Netsmart Technologies for Comprehensive Behavioral Healthcare Integration Project 4Health News:State of Oregon Department of Human Services Selects Netsmart Technologies for Comprehensive Behavioral Healthcare Integration Project 5Health News:ANT+ and iTMP Announce the Digifit™ Ecosystem - The First iPhone™ Apps to Integrate Running, Cycling and Heart Rate Monitoring 2Health News:ANT+ and iTMP Announce the Digifit™ Ecosystem - The First iPhone™ Apps to Integrate Running, Cycling and Heart Rate Monitoring 3Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 2Health News:Board Certified Renal Specialist, Nina Kolbe, Publishes Second Edition of Kidney Health Gourmet: A Diet Guide and Kidney Friendly Recipes for People Not on Dialysis 3Health News:Access to Mammograms Drops After Guidelines Change 2Health News:Bitter melon extract attacks breast cancer cells 2Health News:Belief in a caring god improves response to medical treatment for depression 2
Stylish, elegant and feminine, these attractive frames provide refined and beautiful styles for women ages 40 and older....
The Nine West Eyewear collection is positioned to present today's styles with a sharp, edgy contemporary attitude tied into a clean design element....
The latest MAX MARA eyewear collection has evolved into a harmonious balance of tradition and,leading-edge trend, interpreting timeless themes in an absolutely modern way, yet never losing sight,...
The Liz Claiborne eyewear collection features feminine, classic, progressive friendly designs that meet the needs of today's women. The high quality frames are modern, but not trendy....
Medicine Products: